Home › Markets › Health Care › IQV

IQVIA Holdings Inc. (IQV)

IQV trades on NYSE in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$260.68
-0.58% on the day
Market cap
$42.9B
Large cap
Revenue · 2025
$16.3B
+5.9% on 2024
Net income · 2025
$1.4B
8.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerIQV on NYSE
SectorHealth Care
IndustryBiotechnology: Commercial Physical & Biological Resarch
CountryUnited States
IPO year2013
SEC CIK0001478242
SEC industry codeServices-Commercial Physical & Biological Research
Incorporated inDE

Financials · 2025

LineValue
Revenue$16.3B
Net income$1.4B
Operating income$2.2B
Net margin8.3%
Operating margin13.4%
Revenue growth+5.9%
Cash$2.0B
Total assets$29.9B
P/E (computed)31.5×
P/S (computed)2.6×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32024-01-25
Latest annual report10-K2026-02-17
Latest quarterly / interim10-Q2026-07-28
Latest current report8-K2026-09-23
Latest proxyDEFA14A2026-02-27

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.8%
1 month-2.6%
3 months+24.8%
Year to date+16.6%
1 year+29.0%
From 52-week high-4.5%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Commercial Physical & Biological Resarch

TickerCompanyPriceDayMarket cap
INCYIncyte Corp.$108.62-2.46%$22.0B
MEDPMedpace Holdings Inc.$609.89-1.64%$17.0B
CRLCharles River Laboratories International Inc.$299.02-0.94%$14.3B
ICLRICON plc$164.34-0.04%$12.6B
ABSIAbsci Corporation$9.10-5.89%$1.6B
OABIOmniAb Inc.$4.70-1.47%$683.3M
NRCNRC Health$20.17-1.18%$446.2M
MXCTMaxCyte Inc.$0.9643-3.08%$99.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier